INCLUSION CRITERIA

- Age ≥18 to 65 years. AND

- Proven infection with SARS-CoV-2, defined as detection of SARS-CoV-2 by RT-PCR from
nasopharyngeal swab or lower respiratory tract specimen AND

- Hospitalized at the time of enrollment AND

- HLA Matched Family Related donor with recent SARS-CoV-2 infection is at least 10
days out from symptom onset. A negative result for COVID-19 by a diagnostic test is
not necessary to qualify the donor AND

- In Stage I or II of disease (mild or moderate) at the time of enrollment (Table 1)
AND

- ONE of the following high-risk conditions:

- Chronic lung disease not requiring oxygen at home prior to admission (including
but not limited to COPD, cystic fibrosis, asthma and sickle cell disease);
Underlying heart disease (including hypertension); Patients with an acute
myocardial infarction within the last 3 months will require cardiology
clearance prior to enrollment; Diabetes mellitus (type I or II) ; Obesity (BMI
≥ 30); Immunosuppressed, based on investigator's assessment.

EXCLUSION CRITERIA:

- Stage III disease (severe) at the time of enrollment (see Table 1)

- Lack of an identified eligible HLA family related donor

- No high-risk comorbidities defined in the inclusion criteria (Section 5.1)

- Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of
enrollment

- Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL
Infusion

- Patients with chronic respiratory failure requiring ventilator support and/or oxygen
at home prior to admission are excluded

- Patients with stage D heart failure and/or symptoms at rest are excluded

- Renal function: patients with eGFR or CrCl <30 mL/min/1.73 m2 will be excluded from
study entry.

- Liver function: Total bilirubin > 2 mg/dl (unless Gilbert's syndrome) OR ALT/AST > 5
x ULN

- Patients currently listed for transplant or potentially eligible to receive organ
transplants are excluded from this study

- Patient with poor performance status determined by Karnofsky (patients >16 years) or
Lansky (patients ≤16 years) score ≤50%

- Female patient of childbearing age who is pregnant or breast-feeding or not willing
to use an effective method of birth control during study treatment and for at least
6 weeks after the last dose of SARS-CoV-2 CTLS.

- Male subjects with female partners of childbearing age who are not willing to use an
effective method of birth control during study treatment and for at least 6 weeks
after the last dose of SARS-CoV-2 CTLS.

- Concurrent use of following medications is prohibited:

- Steroids (>2 mg/kg/day prednisone equivalent); Immunotherapies within 4 weeks
prior to CTL infusion including checkpoint blockade, ATG, Campath, CAR T cells,
blinatumomab; Chemotherapy: Tyrosine kinase inhibitors and hydroxyurea must be
stopped > 72 hours prior to SARS-COV-2-CTL cell infusion; High dose
chemotherapy must be stopped > 2 weeks prior to SARS-CoV-2-CTLs. High dose
chemotherapy is defined in this protocol as any cancer directed therapy causing
myelosuppression; Pegylated-asparaginase must be stopped > 4 weeks prior to
SARS-COV-2-CTL infusion; Intrathecal chemotherapy must be stopped > 1 week
prior to SARS-COV-2-CTL infusion (e.g. intrathecal methotrexate); Anti T-cell
Antibodies: Administration of any T cell lytic or toxic antibody (e.g.
alemtuzumab) within 30 days prior to SARS-CoV-2-CTLs is prohibited.